Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04112069 · ClinicalTrials.gov registry record · NA
The Insulin-Only Bionic Pancreas Bridging Study- Pediatric Transitional Study
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT04112069: Completed NA study, sponsored by Massachusetts General Hospital.
NCT04112069 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04112069, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
The iLet is a closed-loop delivery system that can be used in insulin-only, bihormonal, or glucagon-only configurations. Previous studies have utilized a phone-based bionic pancreas. The iLet consists of a touchscreen-enabled, menu-driven user interface and an onboard microprocessor that provides a comprehensive and standalone platform, which allows the iLet to operate independently of smartphones or other devices and without the need for internet support during routine operation. This is a multicenter study of pediatric participants with type 1 diabetes, who will manage their diabetes with the iLet bionic pancreas compared to usual care.
Interventions
- OTHER Usual Care
- DEVICE iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-07-09 |
| Est. Completion | 2018-11-19 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04112069
The ClinicalTrials.gov registry entry for NCT04112069 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Usual Care is the first listed.
NCT04112069 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04112069 about?
NCT04112069 is a clinical study titled "The Insulin-Only Bionic Pancreas Bridging Study- Pediatric Transitional Study". The iLet is a closed-loop delivery system that can be used in insulin-only, bihormonal, or glucagon-only configurations. Previous studies have utilized a phone-based bionic pancreas. The iLet consists of a touchscreen-enabled, menu-driven user interface and an onboard microprocessor that provides a ...
What is the current status of trial NCT04112069?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2018-07-09. Estimated completion is 2018-11-19.
What interventions are being tested in trial NCT04112069?
The interventions under investigation include: Usual Care (OTHER), iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog (DEVICE).
Who is sponsoring clinical trial NCT04112069?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.